Sign in Subscribe

Industry News

M&A, deals, financial results, company news

Alzheimer's disease: 19th CTAD announcement

Mark the date and location on your calendar. 19th Clinical Trials on Alzheimer's Disease Conference November 16-19, 2026 Boston, MA (USA) We're excited to announce that the preliminary program for the upcoming Clinical Trials on Alzheimer's Disease (CTAD) Conference 2026 is now available! This

An update on recent deals

An update on recent deals

In our first two reports of the year, we noted that most biotechnology CEOs were concerned that, after a difficult and "morose" 2025, their companies faced an uncertain future. At the same time, investors had already identified a shift toward higher-value transactions and expected M&A activity

The top 10 pharma R&D budgets of 2025

The top 10 pharma R&D budgets of 2025

According to Fierce Biotech Week, published on March 30, 2026 Top 10 pharma R&D budgets in 2025 Preamble. The top ten pharmaceutical companies with the largest research and development (R&D) budgets in 2025 remain unchanged from the previous year, with only minor shifts in their rankings.

Top European & French Biotech Companies: Recent Developments

Top European & French Biotech Companies: Recent Developments

Overview of Sector Activity Over the past six months, the European biotechnology sector has experienced minimal activity, with no Initial Public Offerings (IPOs), a lack of notable new investments, and no major merger and acquisition announcements. The only significant exception to this subdued landscape has been the remarkable performance of

Feedback from the J.P. Morgan Conference

Feedback from the J.P. Morgan Conference

The 44th Annual J.P. Morgan Healthcare Conference took place from January 12-15, 2026, in San Francisco. Although we have not been present physically in San Francisco, we have been able to connect into several panel discussions and get access to some presentations. Of course, what is missing is the

2025: A turbulent year for the biotechnology industry

2025: A turbulent year for the biotechnology industry

CEOS of biotech companies and financial investors assess the year 2025 with a different viewpoint.

Roche and Alzheimer’s disease

Roche and Alzheimer’s disease

SPECIAL REPORT 25.09 Roche and Alzheimer’s disease On July 28, at the Alzheimer’s Association International Conference (AAIC) held in Toronto (Canada), Roche presented new data from its development portfolio including additional diagnostics outcomes. In several oral presentations Roche disclosed its latest results from the ongoing trontinemab’s